ADHD stories

Jun 2, 2026

FDA Declines Approval of Cingulate's ADHD Treatment Over Manufacturing Concerns

The U.S. Food and Drug Administration rejected Cingulate's drug for attention deficit hyperactivity disorder, citing manufacturing-related issues that need to be resolved before approval can be granted.

Jun 2, 2026·1 source

May 1, 2026

Brain Scans Identify Three Distinct ADHD Subtypes Linked to Different Neural Pathways

New research using brain imaging has revealed three distinct subtypes of ADHD, each associated with different underlying brain systems, co-occurring conditions, and learning challenges. The findings suggest that inattentive and hyperactive-impulsive symptom profiles follow separate neural pathways, potentially enabling more targeted treatment interventions.

May 1, 2026·2 sources

Apr 17, 2026

Buprenorphine Safe for Treating Opioid Addiction During Pregnancy, Study Finds

Children born to mothers who used buprenorphine for opioid addiction during pregnancy show no greater risk of neurodevelopmental disorders like ADHD and autism compared to children whose mothers did not use the medication, providing reassurance about this critical treatment option.

Apr 17, 2026·1 source

Top claims

▪Novartis' Focalin XR uses the same active ingredient as CTx-1301, dexmethylphenidate, but with only a two-stage release.
▪The FDA did not flag any concerns about CTx-1301's safety or effectiveness in its complete response letter to Cingulate.
▪Attention deficit hyperactivity disorder is a neurodevelopmental disorder that can cause persistent inattention, hyperactivity and impulsive behavior, often affecting children and continuing into adulthood.